Obesity disease
Conditions
Interventions
None listed
Sponsors
Asahi Life Foundation Institute of Adult Diseases Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients receiving care at the Asahi Life Foundation Institute of Adult Diseases who meet the following conditions and provide written informed consent to participate in the study 1 Patients with hypertension, dyslipidemia, or impaired glucose tolerance, and who meet one of the following BMI criteria ??- BMI >= 35 kg/m^2, or ??- BMI >= 27 kg/m^2 with at least two obesity related comorbidities. 2 Patients who initiate lifestyle intervention (dietary and exercise counseling) for the purpose of receiving anti obesity pharmacotherapy (semaglutide or tirzepatide).
Exclusion criteria
Exclusion criteria: 1 Patients who are pregnant, or those with severe hepatic or renal dysfunction, or malignant disease. 2 Patients who are using anti-obesity medications other than semaglutide or tirzepatide. 3 Patients whose weight may be affected by recent adjustments in medications such as antidiabetic agents, steroids, antidepressants, or antipsychotic drugs. 4 Patients deemed unsuitable for study participation by the attending physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in visceral fat area, measured by abdominal CT, from the start of lifestyle intervention (baseline) to 6 months after initiation of anti-obesity pharmacotherapy. | — |
Countries
Japan
Contacts
Public ContactShigehisa Nakayama
Asahi Life Foundation Institute of Adult Diseases Hospital General Affairs Section
Outcome results
None listed